Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Digital Event, November 4-7, 2020
Integration of wearable devices into regulated clinical trials for the assessment of cognition and function continues to be a topic of growing interest. If appropriately implemented, measurements from validated wearable technologies have the potential to revolutionize the conduct of clinical trials by facilitating development of site-less clinical trial designs. In order to be truly informative, however, endpoints collected by these devices must undergo the same clinical and technological validation process currently required by other currently accepted tools. This poster reports preliminary findings from an on-going NIH-funded study examining the relationship between real-time measurements of gait and actigraphy collected by industry grade wearable devices and established cognitive and functional endpoints with sensitivity to decline early in the AD continuum.